Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...
A slightly disappointing revenue outlook from Pfizer (PFE) was enough for its COVID-19 vaccine rivals Moderna (MRNA) and Novavax (NVAX) to trade lower on Tuesday, just as a major safety scare related ...
LOS ANGELES (KABC) -- More than 2,000 patients reportedly received a diluted dose of the Pfizer COVID-19 vaccine that were administered at two Los Angeles locations, and they did not find out until 10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback